Targeting the lipid metabolic pathways for the treatment of malaria

Drug Development Research

Volumn 71, Issue 1, 2010, Pages 44-55

  Mamoun, Choukri Ben ^a   Prigge, Sean T ^b   Vial, Henri ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Lipid; Malaria; Metabolism; Plasmodium; Therapy

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN SYNTHASE; ACYL CARRIER PROTEIN; ANTIMALARIAL AGENT; BORTEZOMIB; CITICOLINE; ETHANOLAMINE; ETHANOLAMINE PHOSPHOTRANSFERASE; MILTEFOSINE; PHOSPHATIDYLCHOLINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PROTOZOAL DNA; S ADENOSYLMETHIONINE; SERINE; THIOLACTOMYCIN; TRICLOSAN;

ANTIMALARIAL ACTIVITY; APICOPLAST; BIOSYNTHESIS; CASE REPORT; DRUG TARGETING; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; HUMAN; LIPID METABOLISM; MALARIA; NONHUMAN; PATHOGENESIS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW;

EID: 76749096268     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20347     Document Type: Review

References (89)

1. Aktas M, Narberhaus F. 2009. In vitro characterization of the enzyme properties of the phospholipid N-methyltransferase PmtA from Agrobacterium tumefaciens. J Bacteriol 191:2033-2041.
2. Allary M, Lu JZ, Zhu L, Prigge ST. 2007. Scavenging of the cofactor lipoate is essential for the survival of the malaria parasite Plasmodium falciparum. Mol Microbiol 63:1331-1344.
3. Ancelin ML, Vial HJ. 1986. Quaternary ammonium compounds efficiently inhibit Plasmodium falciparum growth in vitro by impairment of choline transport. Antimicrob Agents Chemother 29:814-820.
4. Ancelin ML, Vial HJ, Philippot JR. 1985. Inhibitors of choline transport into Plasmodium-infected erythrocytes are effective antiplasmodial compounds in vitro. Biochem Pharmacol 34: 4068-4071.
5. Ancelin ML, Parant M, Thuet MJ, Philippot JR, Vial HJ. 1991. Increased permeability to choline in simian erythrocytes after Plasmodium knowlesi infection. Biochem J 273:701-709.
6. Arondel V, Benning C, Somerville CR. 1993. Isolation and functional expression in Escherichia coli of a gene encoding phosphatidylethanolamine methyltransferase (EC 2.1.1.17) from Rhodobacter sphaeroides. J Biol Chem 268:16002-16008.
7. Attard GS, Templer RH, Smith WS, Hunt AN, Jackowski S. 2000. Modulation of CTP:phosphocholine cytidylyltransferase by membrane curvature elastic stress. Proc Natl Acad Sci USA 97: 9032-9036.
8. Beaumelle BD, Vial HJ. 1988. Correlation of the efficiency of fatty acid derivatives in suppressing Plasmodium falciparum growth in culture with their inhibitory effect on acyl-CoA synthetase activity. Mol Biochem Parasitol 28:39-42.
9. Biagini GA, Richier E, Bray PG, Calas M, Vial H, Ward SA. 2003. Heme binding contributes to antimalarial activity of bis-quaternary ammoniums. Antimicrob Agents Chemother 47:2584-2589.
10. Biagini GA, Pasini EM, Hughes R, De Koning HP, Vial HJ, O'Neill PM, Ward SA, Bray PG. 2004. Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs. Blood 104:3372-3377.
11. Bolognese CP, McGraw P. 2000. The isolation and characterization in yeast of a gene for Arabidopsis S-adenosylmethionine:phosphoethanolamine N-methyltransferase. Plant Physiol 124:1800-1813.
12. Brendza KM, Haakenson W, Cahoon RE, Hicks LM, Palavalli LH, Chiapelli BJ, McLaird M, McCarter JP, Williams DJ, Hresko MC, Jez JM. 2007. Phosphoethanolamine N-methyltransferase (PMT-1) catalyzes the first reaction of a new pathway for phosphocholine biosynthesis in Caenorhabditis elegans. Biochem J 404:439-448.
13. Calas M, Ancelin ML, Cordina G, Portefaix P, Piquet G, Vidal-Sailhan V, Vial H. 2000. Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipid metabolism: comparison between mono- and bisquaternary ammonium salts. J Med Chem 43:505-516.
14. Charron JB, Breton G, Danyluk J, Muzac I, Ibrahim RK, Sarhan F. 2002. Molecular and biochemical characterization of a coldregulated phosphoethanolamine N-methyltransferase from wheat. Plant Physiol 129:363-373.
15. Chhibber M, Kumar G, Parasuraman P, Ramya TN, Surolia N, Surolia A. 2006. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg Med Chem 14:8086-8098.
16. Daily JP, Scanfeld D, Pochet N, Le Roch K, Plouffe D, Kamal M, Sarr O, Mboup S, Ndir O, Wypij D, Levasseur K, Thomas E, Tamayo P, Dong C, Zhou Y, Lander ES, Ndiaye D, Wirth D, Winzeler EA, Mesirov JP, Regev A. 2007. Distinct physiological states of Plasmodium falciparum in malaria-infected patients. Nature 450:1091-1095.
17. Davies SM, Epand RM, Kraayenhof R, Cornell RB. 2001. Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy. Biochemistry 40:10522-10531.
18. Divo AA, Geary TG, Davis NL, Jensen JB. 1985. Nutritional requirements of Plasmodium falciparum in culture. I. Exogenously supplied dialyzable components necessary for continuous growth. J Protozool 32:59-64.
19. Elabbadi N, Ancelin ML, Vial HJ. 1997. Phospholipid metabolism of serine in Plasmodium-infected erythrocytes involves phosphatidylserine and direct serine decarboxylation. Biochem J 324:435-445.
20. Florin-Christensen J, Suarez CE, Florin-Christensen M, Hines SA, McElwain TF, Palmer GH. 2000. Phosphatidylcholine formation is the predominant lipid biosynthetic event in the hemoparasite Babesia bovis. Mol Biochem Parasitol 106:147-156.
21. Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, Lucumi E, Kuo M, Jacobs Jr WR, Fidock DA, Schieshser GA, Jacobus DP, Sacchettini JC. 2005. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 40-substituted triclosan derivatives. Bioorg Med Chem Lett 15:5247-5252.
22. Freundlich JS, Yu M, Lucumi E, Kuo M, Tsai HC, Valderramos JC, Karagyozov L, Jacobs Jr WR, Schiehser GA, Fidock DA, Jacobus DP, Sacchettini JC. 2006. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2′-substituted triclosan derivatives. Bioorg Med Chem Lett 16:2163-2169.
23. Freundlich JS, Wang F, Tsai HC, Kuo M, Shieh HM, Anderson JW, Nkrumah LJ, Valderramos JC, Yu M, Kumar TR, Valderramos SG, Jacobs Jr WR, Schiehser GA, Jacobus DP, Fidock DA, Sacchettini JC. 2007. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J Biol Chem 282:25436-25444.
24. Gallagher JR, Prigge ST. 2009. Plasmodium falciparum acyl carrier protein crystal structures in disulfide-linked and reduced states and their prevalence during blood stage growth. Proteins (in press).
25. Gardner MJ, Tettelin H, Carucci DJ, Cummings LM, Aravind L, Koonin EV, Shallom S, Mason T, Yu K, Fujii C, and others. 1998. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science 282:1126-1132.
26. Gardner MJ, Tettelin H, Carucci DJ, Cummings LM, Smith HO, Fraser CM, Venter JC, Hoffman SL. 1999. The malaria genome sequencing project: complete sequence of Plasmodium falciparum chromosome 2. Parasitologia 41:69-75.
27. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, and others. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:49-511.
28. Hamze A, Rubi E, Arnal P, Boisbrun M, Carcel C, Salom-Roig X, Maynadier M, Wein S, Vial H, Calas M. 2005. Mono- and bis-thiazolium salts have potent antimalarial activity. J Med Chem 48:3639-3643.
29. Harwood JL. 1996. Recent advances in the biosynthesis of plant fatty acids. Biochim Biophys Acta 1301:7-56.
30. Holz GG. 1977. Lipids and the malarial parasite. Bull World Health Org 55:237-248.
31. Jones SM, Urch JE, Brun R, Harwood JL, Berry C, Gilbert IH. 2004. Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents. Bioorg Med Chem 12:683-692.
32. Kanipes MI, Hill JE, Henry SA. 1998. The Schizosaccharomyces pombe cho1+ gene encodes a phospholipid methyltransferase. Genetics 150:553-562.
33. Keogh MR, Courtney PD, Kinney AJ, Dewey RE. 2009. Functional characterization of phospholipid N-methyltransferases from Arabidopsis and soybean. J Biol Chem 284:15439-15447.
34. Kirk K, Wong HY, Elford BC, Newbold CI, Ellory JC. 1991. Enhanced choline and Rb1 transport in human erythrocytes infected with the malaria parasite Plasmodium falciparum. Biochem J 278:521-525.
35. Kodaki T, Yamashita S. 1987. Yeast phosphatidylethanolamine methylation pathway. Cloning and characterization of two distinct methyltransferase genes. J Biol Chem 262:15428-15435.
36. Kostrewa D, Winkler FK, Folkers G, Scapozza L, Perozzo R. 2005. The crystal structure of PfFabZ, the unique beta-hydroxyacyl-ACP dehydratase involved in fatty acid biosynthesis of Plasmodium falciparum. Protein Sci 14:1570-1580.
37. Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WRJ, Sacchettini JC, Fidock DA. 2003. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 278:20851-20859.
38. Lack G, Homberger-Zizzari E, Folkers G, Scapozza L, Perozzo R. 2006. Recombinant expression and biochemical characterization of the unique elongating beta-ketoacyl-acyl carrier protein synthase involved in fatty acid biosynthesis of Plasmodium falciparum using natural and artificial substrates. J Biol Chem 281:9538-9546.
39. Lee PJ, Bhonsle JB, Gaona HW, Huddler DP, Heady TN, Kreishman-Deitrick M, Bhattacharjee A, McCalmont WF, Gerena L, Lopez-Sanchez M, Roncal NE, Hudson TH, Johnson JD, Prigge ST, Waters NC. 2009. Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents. J Med Chem 52:952-963.
40. Lehane AM, Saliba KJ, Allen RJ, Kirk K. 2004. Choline uptake into the malaria parasite is energized by the membrane potential. Biochem Biophys Res Commun 320:311-317.
41. Lemieux JE, Gomez-Escobar N, Feller A, Carret C, Amambua-Ngwa A, Pinches R, Day F, Kyes SA, Conway DJ, Holmes CC, Newbold CI. 2009. Statistical estimation of cell-cycle progression and lineage commitment in Plasmodium falciparum reveals a homogeneous pattern of transcription in ex vivo culture. Proc Natl Acad Sci USA 106:7559-7564.
42. Le Roch KG, Johnson JR, Ahiboh H, Chung DW, Prudhomme J, Plouffe D, Henson K, Zhou Y, Witola W, Yates JR, Mamoun CB, Winzeler EA, Vial H. 2008. A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum. BMC Genomics 9:513.
43. Lu JZ, Lee PJ, Waters NC, Prigge ST. 2005. Fatty acid synthesis as a target for antimalarial drug discovery. Comb Chem High Throughput Screen 8:15-26.
44. Magnuson K, Jackowski S, Rock CO, Cronan Jr JE. 1993. Regulation of fatty acid biosynthesis in Escherichia coli. Microbiol Rev 57:522-542.
45. McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE. 2001. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of Apicomplexan Fab I. Int J Parasitol 31:109-113.
46. Mitamura T, Hanada K, Ko-Mitamura EP, Nishijima M, Horii T. 2000. Serum factors governing intraerythrocytic development and cell cycle progression of Plasmodium falciparum. Parasitol Int 49:219-229.
47. Moll GN, Vial HJ, Ancelin ML, Op den Kamp JA, Roelofsen B, van Deenen LL. 1988. Phospholipid uptake by Plasmodium knowlesi infected erythrocytes. FEBS Lett 232:341-346.
48. Muench SP, Prigge ST, McLeod R, Rafferty JB, Kirisits MJ, Roberts CW, Mui EJ, Rice DW. 2007. Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents. Acta Crystallogr D Biol Crystallogr 63:328-338.
49. Nicola G, Smith CA, Lucumi E, Kuo MR, Karagyozov L, Fidock DA, Sacchettini JC, Abagyan R. 2007. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening. Biochem Biophys Res Commun 358:686-691.
50. Nuccio ML, Ziemak MJ, Henry SA, Weretilnyk EA, Hanson AD. 2000a. cDNA cloning of phosphoethanolamine N-methyltransferase from spinach by complementation in Schizosaccharomyces pombe and characterization of the recombinant enzyme. J Biol Chem 275:14095-14101.
51. Nuccio ML, Ziemak MJ, Henry SA, Weretilnyk EA, Hanson AD. 2000b. cDNA cloning of phosphoethanolamine N-methyltransferase from spinach by complementation in Schizosaccharomyces pombe and characterization of the recombinant enzyme. J Biol Chem 275:14095-14101.
52. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, editors. 1991. Malaria: obstacles and opportunities. Washington, DC: National Academy Press. 309p.
53. Palavalli LH, Brendza KM, Haakenson W, Cahoon RE, McLaird M, Hicks LM, McCarter JP, Williams DJ, Hresko MC, Jez JM. 2006. Defining the role of phosphomethylethanolamine N-methyltransferase from Caenorhabditis elegans in phosphocholine biosynthesis by biochemical and kinetic analysis. Biochemistry 45: 6056-6065.
54. Perozzo R, Kuo M, Sidhu AbS, Valiyaveettil JT, Bittman R, Jacobs Jr WR, Fidock DA, Sacchettini JC. 2002. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J Biol Chem 277: 13106-13114.
55. Pessi G, Ben Mamoun C. 2006. Pathways for phosphatidylcholine biosynthesis: targets and strategies for antimalarial drugs. Future Med, Future Lipidol 1:173-180.
56. Pessi G, Kociubinski G, Mamoun CB. 2004. A pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylation. Proc Natl Acad Sci USA 101:6206-6211.
57. Pessi G, Choi JY, Reynolds JM, Voelker DR, Mamoun CB. 2005. In vivo evidence for the specificity of Plasmodium falciparum phosphoethanolamine methyltransferase and its coupling to the Kennedy pathway. J Biol Chem 280:12461-12466.
58. Pidugu LS, Kapoor M, Surolia N, Surolia A, Suguna K. 2004. Structural basis for the variation in triclosan affinity to enoyl reductases. J Mol Biol 343:147-155.
59. Pillai S, Rajagopal C, Kapoor M, Kumar G, Gupta A, Surolia N. 2003. Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun 303:387-392.
60. Prigge ST, He X, Gerena L, Waters NC, Reynolds KA. 2003. The initiating steps of a type II fatty acid synthase in Plasmodium falciparum are catalyzed by pfACP, pfMCAT, and pfKASIII. Biochemistry 42:1160-1169.
61. Reynolds JM, Takebe S, Choi JY, El Bissati K, Witola WH, Bobenchik AM, Hoch JC, Voelker DR, Mamoun CB. 2008. Biochemical and genetic analysis of the phosphoethanolamine methyltransferase of the human malaria parasite Plasmodium falciparum. J Biol Chem 283:7894-7900.
62. Richier E, Biagini GA, Wein S, Boudou F, Bray PG, Ward SA, Precigout E, Calas M, Dubremetz JF, Vial HJ. 2006. Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp. Antimicrob Agents Chemother 50:3381-3388.
63. Rock CO, Cronan JE. 1996. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim Biophys Acta 1302:1-16.
64. Scheibel LW, Sherman IW. 1988. Plasmodial metabolism and related organellar function during various stages of the life-cycle: proteins, lipids, nucleic acids and vitamins. In: Wernsdorfer W, McGregor I, editors. Principles and practice of malariology. New York: Churchill Livingstone. p 219-252.
65. Sharma SK, Kapoor M, Ramya TN, Kumar S, Kumar G, Modak R, Sharma S, Surolia N, Surolia A. 2003. Identification, characterization, and inhibition of Plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J Biol Chem 278:45661-45671.
66. Spalding MD, Prigge ST. 2008. Malaria pulls a FASt one. Cell Host Microbe 4:509-511.
67. Summers EF, Letts VA, McGraw P, Henry SA. 1988. Saccharomyces cerevisiae cho2 mutants are deficient in phospholipid methylation and cross-pathway regulation of inositol synthesis. Genetics 120:909-922.
68. Surolia N, Surolia A. 2001. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med 7:167-173.
69. Swarnamukhi PL, Sharma SK, Bajaj P, Surolia N, Surolia A, Suguna K. 2006. Crystal structure of dimeric FabZ of Plasmodium falciparum reveals conformational switching to active hexamers by peptide flips. FEBS Lett 580:2653-2660.
70. Swarnamukhi PL, Sharma SK, Padala P, Surolia N, Surolia A, Suguna K. 2007. Packing and loop-structure variations in nonisomorphous crystals of FabZ from Plasmodium falciparum. Acta Crystallogr D Biol Crystallogr 63:458-464.
71. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
72. Vance DE, Li Z, Jacobs RL. 2007. Hepatic phosphatidylethanolamine N-methyltransferase, unexpected roles in animal biochemistry and physiology. J Biol Chem 282:33237-33241.
73. Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH. 2009. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11:506-520.
74. Vial H, Ancelin M. 1998. Malarial Lipids. In: Sherman I, editor. Malaria: parasite biology, biogenesis, protection. Washington, DC: ASM Press. p 159-175.
75. Vial HJ, Ben Mamoun C. 2005. Plasmodium lipids: metabolism and Function. In: Sherman IW, editor. Molecular approaches to malaria. Washington, DC: ASM Press. p 327-352.
76. Vial HJ, Thuet MJ, Ancelin ML, Philippot JR, Chavis C. 1984. Phospholipid metabolism as a new target for malaria chemotherapy. Mechanism of action of D-2-amino-1-butanol. Biochem Pharmacol 33:2761-2770.
77. Vial HJ, Ancelin ML, Philippot JR, Thuet MJ. 1990. Biosynthesis and dynamics of lipids in Plasmodium-infected mature mammalian erythrocytes. Blood Cells 16:531-555; discussion 556-561.
78. Vial HJ, Wein S, Farenc C, Kocken C, Nicolas O, Ancelin ML, Bressolle F, Thomas A, Calas M. 2004. Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc Natl Acad Sci USA 101:15458-15463.
79. Waller RF, Keeling PJ, Donald RG, Striepen B, Handman E, Lang-Unnasch N, Cowman AF, Besra GS, Roos DS, McFadden GI. 1998. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc Natl Acad Sci USA 95:12352-12357.
80. Waller RF, Ralph SA, Reed MB, Su V, Douglas JD, Minnikin DE, Cowman AF, Besra GS, McFadden GI. 2003. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob Agents Chemother 47: 297-301.
81. Waller RF, Reed MB, Cowman AF, McFadden GI. 2000. Protein trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. Embo J 19:1794-1802.
82. Waters NC, Kopydlowski KM, Guszczynski T, Wei L, Sellers P, Ferlan JT, Lee PJ, Li Z, Woodard CL, Shallom S. 2002. Functional characterization of the acyl carrier protein (PfACP) and beta-ketoacyl ACP synthase III (PfKASIII) from Plasmodium falciparum. Mol Biochem Parasitol 123:85-94.
83. Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, Calas M, Herrera S, Thomas AW, Vial HJ. 2002. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 295:1311-1314.
84. Wickramasinghe SR, Inglis KA, Urch JE, Muller S, van Aalten DM, Fairlamb AH. 2006. Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochem J 393:447-457.
85. Wirth D, Daily J, Winzeler E, Mesirov JP, Regev A. 2009. In vivo profiles in malaria are consistent with a novel physiological state. Proc Natl Acad Sci USA 106:E70; author reply E71-E72.
86. Witola WH, Ben Mamoun C. 2007. Choline induces transcriptional repression and proteasomal degradation of the malarial phosphoethanolamine methyltransferase. Eukaryot Cell 6: 1618-1624.
87. Witola WH, Pessi G, El Bissati K, Reynolds JM, Mamoun CB. 2006. Localization of the phosphoethanolamine methyltransferase of the human malaria parasite Plasmodium falciparum to the Golgi apparatus. J Biol Chem 281:21305-21311.
88. Witola WH, El Bissati K, Pessi G, Xie C, Roepe PD, Mamoun CB. 2008. Disruption of the Plasmodium falciparum PfPMT gene results in a complete loss of phosphatidylcholine biosynthesis via the serine-decarboxylase- phosphoethanolamine-methyltransferase pathway and severe growth and survival defects. J Biol Chem 283:27636-27643.
89. Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, and others. 2008. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4:567-578.